27563235|t|Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor - targeted cancer therapy
27563235|a|Fibroblast growth factor receptors (FGFRs) are attractive candidate cancer therapy targets as they are overexpressed in multiple types of tumors, such as breast, prostate, bladder, and lung cancer. In this study, a natural ligand of FGFR, an engineered variant of fibroblast growth factor 1 (FGF1V), was conjugated to a potent cytotoxic drug, monomethyl auristatin E (MMAE), and used as a targeting agent for cancer cells overexpressing FGFRs, similar to antibodies in antibody-drug conjugates. The FGF1V-valine-citrulline-MMAE conjugate showed a favorable stability profile, bound FGFRs on the cell surface specifically, and efficiently released the drug (MMAE) upon cleavage by the lysosomal protease cathepsin B. Importantly, the conjugate showed a prominent cytotoxic effect toward cell lines expressing FGFR. FGF1V-vcMMAE was highly cytotoxic at concentrations even an order of magnitude lower than those found for free MMAE. This effect was FGFR -specific as cells lacking FGFR did not show any increased mortality.
27563235	40	66	fibroblast growth factor 1	T103	UMLS:C0079349
27563235	67	76	conjugate	T103	UMLS:C1254351
27563235	81	114	fibroblast growth factor receptor	T103	UMLS:C0060369
27563235	117	140	targeted cancer therapy	T058	UMLS:C3854476
27563235	141	175	Fibroblast growth factor receptors	T103	UMLS:C0060369
27563235	177	182	FGFRs	T103	UMLS:C0060369
27563235	209	223	cancer therapy	T058	UMLS:C0920425
27563235	244	257	overexpressed	T038	UMLS:C1514559
27563235	279	285	tumors	T038	UMLS:C0027651
27563235	295	301	breast	T038	UMLS:C1458155
27563235	303	311	prostate	T038	UMLS:C0033578
27563235	313	320	bladder	T038	UMLS:C0005695
27563235	326	337	lung cancer	T038	UMLS:C0242379
27563235	356	370	natural ligand	T038	UMLS:C1749457
27563235	374	378	FGFR	T103	UMLS:C0060369
27563235	383	401	engineered variant	T103	UMLS:C0034861
27563235	405	431	fibroblast growth factor 1	T103	UMLS:C0079349
27563235	433	438	FGF1V	T103	UMLS:C0079349
27563235	445	455	conjugated	T082	UMLS:C0522529
27563235	461	482	potent cytotoxic drug	T103	UMLS:C0304497
27563235	484	507	monomethyl auristatin E	T103	UMLS:C1565020
27563235	509	513	MMAE	T103	UMLS:C1565020
27563235	530	545	targeting agent	T038	UMLS:C0599894
27563235	550	562	cancer cells	T017	UMLS:C0334227
27563235	563	577	overexpressing	T038	UMLS:C1514559
27563235	578	583	FGFRs	T103	UMLS:C0060369
27563235	596	606	antibodies	T103	UMLS:C0003241
27563235	610	634	antibody-drug conjugates	T058	UMLS:C2346828
27563235	640	678	FGF1V-valine-citrulline-MMAE conjugate	T103	UMLS:C1254351
27563235	698	715	stability profile	T038	UMLS:C1327386
27563235	717	722	bound	T038	UMLS:C1167622
27563235	723	728	FGFRs	T103	UMLS:C0060369
27563235	736	748	cell surface	T017	UMLS:C0699040
27563235	792	803	drug (MMAE)	T103	UMLS:C1565020
27563235	809	817	cleavage	T038	UMLS:C0597304
27563235	825	855	lysosomal protease cathepsin B	T103	UMLS:C0699919
27563235	874	883	conjugate	T103	UMLS:C1254351
27563235	903	919	cytotoxic effect	T038	UMLS:C0596402
27563235	927	937	cell lines	T017	UMLS:C0334227
27563235	949	953	FGFR	T103	UMLS:C0060369
27563235	955	967	FGF1V-vcMMAE	T103	UMLS:C1254351
27563235	1066	1070	MMAE	T103	UMLS:C1565020
27563235	1088	1092	FGFR	T103	UMLS:C0060369
27563235	1106	1111	cells	T017	UMLS:C0334227
27563235	1120	1124	FGFR	T103	UMLS:C0060369
27563235	1125	1137	did not show	T033	UMLS:C1513916
27563235	1152	1161	mortality	T038	UMLS:C0007587